Amarin Corp Plc (AMRN)

[Whalatane]

BBI. well a note of caution here, before you all high 5 each other .
BRAVE is a small study ( 150 patients for 18 mths ...from memory ) . So based on my limited bio stat knowledge its underpowered to show stat sig results ...Tasty and others are welcome to correct me if necessary .
To generate a P value of less then .05 ...which is the generally accepted minimum to rule out the results U see are by chance ...U normally need larger numbers enrolled for longer periods

The more knowledgeable posters on bio stats please correct me if necessary .
So at best U are likely to see is a " trend towards "...or " associated with "...and a call for a far larger trial for longer periods.

So we are a long way from your "possible home run ".

Meanwhile we are 26 days away from everyone in the V arm of MITIGATE completing the 12 mths on drug as per trial design .
By the end of the first week of Sept , Kaiser is likely to know ...if their EHR ( in-house record keeping ) is a good as some say it is .....wether Vascepa reduces risk of hospitalization or severe outcomes from Covid .
They will need to "clean" and recheck their data before publishing / presenting .....but if ..and thats BUT IF ...this data shows less ..statistically significant ....risk of hospitalization or severe outcome adding Vascepa to the high risk population studied ...then I expect Kaiser to dispense V to all their CV patients that meet the studies inclusion criteria .

Thats your near term possible " home run ".

Kiwi